Clinical application of pharmacogenetics in gastrointestinal diseases. (Q36613862)

15 August 2017

title

Clinical application of pharmacogenetics in gastrointestinal diseases. (English)

1 reference

15 August 2017

Michael Camilleri

1 reference

15 August 2017

Yuri A Saito

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

1857-1869

1 reference

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Review article: the genetics of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Frequency of glucocorticoid resistance and dependency in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Small bowel malignancy at diagnosis of coeliac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Pharmacogenetics of the proton pump inhibitors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

AGA technical review on irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Serotonin transporter gene polymorphism in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Pathophysiology and treatment of functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Functional genomics approaches in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

G-protein beta3 subunit 825T allele and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Increased transcriptional activity of the CYP3A4*1B promoter variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Epidemiology and prevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

ABC of colorectal cancer: Epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Pharmacogenomics in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1857

10.1517/14656566.7.14.1857

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference